

Efforts to Help People with Disabilities & Severe Illnesses from COVID-19, Launched by OMGENEUM BIOPHARMA

OMGENEUM Inc., Launches OMGENEUM BIOPHARMA, a Spin-Out Company, Established to Help Protect the Most Vulnerable People Suffering with Disabilities and Severe Illnesses from the Deadly COVID-19 Coronavirus Global Pandemic.



Tokyo, Apr 9, 2020 ([Issuewire.com](https://www.issuewire.com)) - OmGeneum Inc., is a regenerative bio-engineering company developing next-generation technologies to cure devastating brain diseases, injuries and, disorders has announced the establishment of OmGeneum Biopharma, a spin-out to help the most vulnerable people with disabilities and intractable diseases combat the novel coronavirus global pandemic.

The World Health Organization declared the novel coronavirus outbreak a global "pandemic." WHO's director-general, Tedros Adhanom Ghebreyesus said, "We have called every day for countries to take urgent and aggressive action."

Currently, many countries are now moving at record speed to protect their citizens by increasing the number of innovative testing methods for the novel coronavirus, including drive-through testing stations.

The Center for Disease Control and Prevention (CDC) data shows that people of any age who have underlying medical conditions, disabilities, or the elderly have a higher risk for severe illness or death

from COVID-19 disease.

Tragically, many people with disabilities and incurable diseases, such as Alzheimer's dementia, cannot travel to drive-through testing stations or to hospitals where asymptomatic people could them with the deadly contagious virus.

James Ryan's -OmGeneum's CEO- son suffered a devastating brain injury and with disabilities from the age of five months old and has been connected to mechanical ventilation with from age of eleven yrs. old.

"Our family is living with fear, our son Jimmy has the highest risk of dying if infected with the deadly coronavirus, so it is critically important that our most vulnerable, who know it's impossible to travel to a drive-through testing station, have access to early-stage COVID-19 home-testing kits," said James Ryan, OMGENEUM's CEO. "My son, along with millions of other vulnerable people throughout the world are in the same desperate situation."

"We established an NGO, ["Jimmy's Fight"](#), to collaborate with disability organizations, advocacy groups and charities with the aim to help donate COVID-19 home-testing kits, and personal protective gear to those who aren't able to travel to a drive-through station."

"After years of relentless effort, we just recently had a technology breakthrough that we truly believe can help regenerate Jimmy's damaged brain," said James Ryan. "Jimmy's fought so hard to survive, he deserves more time and basic human "Rights-to-Try".

Having the "Right-to-Try" diagnostic tests for novel coronavirus COVID-19 disease at home could help protect patients, physicians and many others avoid the danger of coronavirus.

The rapid COVID-19 home-testing kits received a CE marking, enabling OmGeneum BioPharma to market and sell in the EU. OmGeneum Biopharma is announcing that it is seeking FDA emergency use authorization (EUA) for rapid COVID-19 home-testing kits for the USA market.

To learn more about OmGeneum and OmGeneum BioPharma, or, get involved, please click on the below links.

About OmGeneum BioPharma is an OmGeneum spin-out, as an insightful digital Health-Tech Startup providing diagnostic tests, at home-testing kits, Tele-health services and provide personal protective equipment.

<http://www.omgeneumbiopharma.com/>

About OmGeneum

OmGeneum is regenerative bio-engineering company developing next-generation technology to precisely target, modulate and augment endogenous tissue/organs/cell regeneration, and exponentially improve regenerative (stem cell) medicine treatments for devastating neurological diseases, dysfunctions, and disorders for patients with high unmet medical needs worldwide, as the existing medical treatments are ineffective.

For more information, visit: <https://www.omgeneumusa.com/>

Public Relations: pr@omgeneum.com



Media Contact

OmGeneum BioPharma

jr@omgeneum.com

81-50-5534-9002

Mikkabi-Cho 3103-1Tsuzuki Kita Ward,

Source : Omgeneum Inc.

[See on IssueWire](#)